Product Code: RP-ID-10078575 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10078575
Market Overview:
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segmentation by Treatment (Plasmapheresis, Corticosteriods, and Intravenous Immunoglobulin); by End-Users (Clinics, Hospitals, Research and Academic Institutes, and Others); by Route of Administration (Injectable, and Oral)-Global Demand Analysis & Opportunity Outlook 2031
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Highlights Over 2022 - 2031
The global chronic inflammatory demyelinating polyneuropathy (CIDP) market is estimated to grow at a ~8% CAGR over the forecast period, i.e., 2022 – 2031. Moreover, the market registered a revenue of approximately USD 4 Billion in 2021. The growth of the market can be attributed to growing research for the treatment of CIDP and an increase in healthcare expenditure. As per the World Health Organization, global spending on health has reached USD 8.3 trillion or 10 percent of the GDP. Moreover, there has been a rise in government support for awareness among the population that is anticipated to drive the growth of the global chronic inflammatory demyelinating polyneuropathy (CIDP) market.
GET A SAMPLE COPY OF THIS REPORT
The global chronic inflammatory demyelinating polyneuropathy (CIDP) market is segmented by treatment into plasmapheresis, corticosteroids, and intravenous immunoglobulin. Out of these, the intravenous immunoglobulin segment is anticipated to hold the largest share over the forecast period in the global chronic inflammatory demyelinating (CIDP) market owing to the faster response and greater chance of reducing the disability. As per the National Library of Medicine, several trails showed a response rate of 60 percent over 24 weeks of IVIg during a short observation period.
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Regional Synopsis
Regionally, the global chronic inflammatory demyelinating polyneuropathy (CIDP) market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. Backed by the increase in the CIDP cases and the rise in the awareness program, the market in the North America region is anticipated to hold the largest share by the end of 2031. According to the American Association of Neuromuscular & Electrodiagnostic Medicine, nearly 30,000 patients are affected by CIDP at any one time. The market in the Asia Pacific region is estimated to witness modest growth over the forecast period on the back of the increase in the percentage of the population that is anticipated to have the prevalence of the chronic inflammatory demyelinating (CIDP) market in the region.
Market Segmentation
Our in-depth analysis of the global chronic inflammatory demyelinating polyneuropathy (CIDP) market includes the following segments:
By Treatment
-
Plasmapheresis
-
Corticosteriods
-
Intravenous Immunoglobulin
By End-Users
-
Clinics
-
Hospitals
-
Research and Academic Institutes
-
Others
By Route of Administration
-
Injectable
-
Oral
Growth Drivers and Challenges Impacting the Growth of the Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
Growth Drivers
-
Growing research for the treatment of CIDP
-
Increase in the healthcare expenditure
Challenges
-
High price of the drugs
-
Lack of awareness related to treatment options
Key Companies Dominating the Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global chronic inflammatory demyelinating polyneuropathy (CIDP) market that are included in our report are AbbVie Inc., Pfizer Inc., Astellas Pharma Inc., GeNeuro SA, Bio Products Laboratory Ltd., TEIJIN LIMITED., Baxter., Octapharma AG, Grifols, S.A., Mitsubishi Chemical Holding Corporation., and others.
Latest Developments in the Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market:
-
16 May 2022: AbbVie Inc., and Cugene announced the collaboration for the treatment of autoimmune and inflammatory diseases. The purpose of the collaboration is to develop and advance potential next-generation therapie like CUG252.
-
29 July 2021: Baxter International Inc., announced the acquisition of certain assets from CryoLife, Inc., that augment and complement the company’s leading portfolio across the hospital.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis, and challenges that impact market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the client's requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
- AbbVie Inc.
- Pfizer Inc.
- Astellas Pharma Inc.
- GeNeuro SA
- Bio Products Laboratory Ltd.
- TEIJIN LIMITED.
- Baxter.
- Octapharma AG
- Grifols S.A.
- Mitsubishi Chemical Holding Corporation.
Related Reports
Proof of Quality & Reliability
